This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
by Zacks Equity Research
Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
by Zacks Equity Research
DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.
Abbott's Core Businesses Thrive Despite Macroeconomic Issues
by Zacks Equity Research
ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.
The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace
by Zacks Equity Research
Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.
Top Research Reports for Eli Lilly, Chevron & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).
Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Abbott (ABT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $112.10, moving +0.64% from the previous trading session.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?
by Urmimala Biswas
Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
by Zacks Equity Research
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?
by Urmimala Biswas
Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.
Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall
by Zacks Equity Research
Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
by Zacks Equity Research
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook
by Zacks Equity Research
National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
by Zacks Equity Research
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
by Zacks Equity Research
CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.